Report library

Triple-Negative Breast Cancer KOL Interview – US

A US-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple- negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include balixafortide, Keytruda, sacituzumab govitecan, trastuzumab deruxtecan, and veliparib.

October 3, 2019

Live-attenuated RSV vaccines

In collaboration with the National Institute of Allergy and Infectious Diseases, AstraZeneca is developing a portfolio of three live-attenuated vaccines for the prevention of serious lower respiratory tract infections.

October 5, 2018

Market Spotlight: Hereditary Angioedema

$1,318.00

This Market Spotlight report covers the Hereditary Angioedema market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

August 23, 2022

Ovarian Cancer KOL Interview – UK

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for ovarian cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include veliparib, mirvetuximab soravtansine, Recentin, ofranergene obadenovec, dostarlimab, Tecentriq, Keytruda, Imfinzi, and Opdivo.

April 2, 2020

Pulmonary Hypertension KOL Interview – US #2

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Tyvaso, Tyvaso DPI, Yutrepia, Letairis, Opsumit, Uptravi, Remodulin, Adcirca, sotatercept, INOpulse, and ralinepag.

July 21, 2022

F/TAF

F/TAF (emtricitabine/tenofovir alafenamide fumarate [TAF]; Gilead) is a fixed-dose combination of two of Gilead’s nucleoside reverse transcriptase inhibitors, Emtriva (emtricitabine) and GS-7340 (TAF).

December 11, 2015

V180

Merck & Co’s adjuvanted, tetravalent subunit vaccine V180 comprises truncated forms of envelope proteins (DEN-80E), derived from strains of all four dengue virus serotypes (DEN-1 strain 258848, DEN-2 strain PR159 S1, DEN-3 strain CH53489, and DEN-4 strain H241).

January 4, 2018

Rheumatoid Arthritis KOL Interview – UK

A UK-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

July 31, 2019

Oncology Pathways in the US – Friend or Foe for Pharma

$7,500.00

This strategy report focuses on Oncology Pathways in the US including management of oncology costs, oncology clinical pathway programs and developers, impact of pathways on oncology, and the future of oncology pathways.

July 31, 2015

Extremity Replacement Implants

This medical market and technology report provides a comprehensive discussion of the global market for extremities replacement implants. Market forecasts and competitive analyses are provided for the shoulder, elbow, ankle, and small joint arthroplasty devices markets. Geographic segments covered by this analysis comprise the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW) markets, which includes all other countries.

December 21, 2020

Pulmonary Hypertension KOL Interview – US #1

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Tyvaso, Tyvaso DPI, Yutrepia, Adempas, Letairis, Opsumit, Orenitram, Uptravi, Remodulin, Adcirca, sotatercept, INOpulse, and ralinepag.

July 21, 2022

tislelizumab

Tislelizumab (BeiGene) is a humanized monoclonal antibody that was designed to bind to the PD-1 receptor and prevent binding of PD-L1. In addition, tislelizumab was designed to minimize binding to Fc-gamma-receptors (FcyR) on macrophages.

September 9, 2019

Mid Pharma Licensing and M&A Trends, 2011–16

$2,995.00

This analysis covers trends in alliance and mergers and acquisitions (M&A) agreements by Datamonitor Healthcare’s Mid Pharma peer set from 1 January 2011 through to 30 September 2016. Only deals involving drug discovery, development, or commercialization were considered for this analysis. All data were derived from Informa’s Strategic Transactions and Medtrack databases.

February 16, 2017

Bosulif

Bosulif is a kinase inhibitor that targets the BCR-ABL kinase and also inhibits the Src-family kinases that include Src, Lyn, and Hck. The BCR-ABL kinase is upregulated in the presence of an abnormal BCR-ABL fusion protein…

December 7, 2017

Entinostat

Entinostat is a class I selective histone deacetylase (HDAC) inhibitor. HDACs influence the expression of genes involved in both the initiation of cancer

February 5, 2016

U.S. Markets for Interventional Peripheral Vascular Disease Management Products and Technologies

This dynamic, new report from Medtech Insight includes analyses of products, current and forecast markets, competitors, and opportunities in the U.S. interventional peripheral vascular disease management arena.

September 22, 2016

U.S. Markets, Trends, and Opportunities in Patient Monitoring Products

The intensity and high acuity of the critical care environment, combined with the shortage of experienced registered nurses, means that noninvasive and minimally invasive patient monitoring products will be in great demand during the forecast period covered by this report.

November 1, 2013

Interventional Cardiology: Implantable Pacemaker Products

In 2020, the global market for implantable pacemaker products totaled nearly $3.9bn, with dual-chamber products accounting for nearly 75% of sales. Over the forecast period covered by this report, single-chamber pacemaker devices are expected to experience greater growth than the dual-chamber market, advancing at a CAGR of approximately 6.8%. Drivers include a growing prevalence of cardiovascular disease due to the aging population, the development of leadless pacemaker systems, and expanded indications. Additionally, there is strong evidence of a correlation between COVID-19 and the development of atrial arrythmias.

November 11, 2021

Pneumococcal Vaccines KOL Interview

Datamonitor interviewed three infectious diseases specialists to determine the physicians’ views on marketed and pipeline pneumococcal vaccines. Two physicians were based in Chicago, IL and one in the UK. The three interviews were combined into a single report.

August 27, 2016

Company Analysis : AbbVie

$3,000.00

PharmaVitae explores AbbVie’s prescription pharmaceutical performance and outlook over 2019–29.

July 15, 2020

GSK-3003891A

GSK-3003891A (GlaxoSmithKline) is an alum-adjuvanted respiratory syncytial virus (RSV) vaccine based on the prefusion form of the RSV fusion (F) protein. It is currently in Phase II development in the US and EU.

October 5, 2018

Orenitram

United Therapeutics’ Orenitram (trepostinil) is the first-to-market oral formulation of a prostacyclin analog, and is a reformulation of the company’s intravenous prostacyclin analog Remodulin.

October 19, 2018

Abilify/Abilify Maintena

Abilify (aripiprazole; Otsuka/Lundbeck) is an atypical antipsychotic that contains aripiprazole, a partial agonist of dopamine receptor D2 and serotonin receptor 5-HT1A, and antagonist of the 5-HT2A receptor.

March 29, 2019

Remicade

Remicade (infliximab; Johnson & Johnson/Merck & Co/Mitsubishi Tanabe) is a chimeric, humanized monoclonal antibody targeting tumor necrosis factor (TNF)-alpha, with a long history of use in a number of immune-mediated inflammatory diseases, including Crohn’s disease, rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, Behçet’s syndrome, and ulcerative colitis.

August 2, 2018

Rytary

Rytary (Impax Laboratories) is a novel oral capsule formulation of carbidopa and levodopa that contains both an immediate-release and a sustained-release levodopa component.

June 21, 2018

HIV Disease Coverage Forecast and Market Analysis to 2027

The human immunodeficiency virus, or HIV, is a retrovirus that infects the cells of the immune system such as T lymphocytes, specifically cluster of differentiation-4+ T cells, dendritic cells, and macrophages.

June 28, 2019

Dyslipidemia and Diabetes Reimbursement KOL Interview:

Topics: Dyslipidemia and Diabetes Reimbursement PCSK9 Inhibitors, SGLT2/DPP4 Inhibitor FDCs, and Biosimilar Insulin

August 5, 2015

US Neurointerventional Devices Market

Neurointerventional radiology/surgery, or neurovascular intervention, is a relatively new medical specialty employing minimally invasive endovascular techniques to treat vascular diseases of the brain. Neurointerventional devices, which contributed sales of more than $870m in the US in 2015, involve a variety of standard and application-specific transcatheter tools and techniques for the treatment of cerebrovascular pathologies (such as aneurysms, arteriovenous malformations [AVMs], and acute and chronic thromboembolic and atherosclerotic occlusions) that prompt clinically significant distortions of cerebral blood flow and carry a high risk of catastrophic breakdowns of cerebrovascular circulation manifested by hemorrhagic or ischemic stroke.

September 21, 2016

Nucala

Nucala (mepolizumab; GlaxoSmithKline) is a humanized monoclonal immunoglobulin G1 antibody that binds to interleukin (IL)-5, which plays a significant role in the activation, proliferation, and differentiation of eosinophils.

July 31, 2018

Glembatumumab Vedotin

Glembatumumab vedotin (Celldex) is an antibody–drug conjugate that targets cancer cells expressing glycoprotein non-metastatic B.

April 15, 2016

Market Spotlight: Endometriosis

$1,318.00

This Market Spotlight report covers the Endometriosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

June 9, 2022

MEDI8897

MEDI8897 is a human immunoglobulin G1 MAb derived from human B cells intended to provide protection against RSV infection.

October 5, 2018

Angioplasty Catheters Market

This comprehensive medical market and technology report provides an overview and in-depth market analysis of angioplasty catheters, specifically plain old balloon angioplasty (POBA), drug-coated balloon (DCB), cutting balloon, and scoring balloon catheters, used in the treatment of severe coronary artery disease (CAD) and peripheral artery disease (PAD).

November 28, 2017

Squalamine

Ohr Pharmaceutical will aim to make squalamine (OHR-102) the first topical treatment approved for

wet age-related macular degeneration (AMD)

September 8, 2017

Heart Valve Repair and Replacement Devices Market

The global market for heart valve repair and replacement devices is being driven by the increasing burden of heart valve disease, which left untreated can lead to severe and life-threatening cardiovascular diseases. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the worldwide heart valve repair and replacement devices market, which includes percutaneous balloon valvuloplasty, heart valve surgery, transcatheter aortic valve replacement (TAVR), and transcatheter mitral valve regurgitation therapy (TMVrep). Global heart valve repair and replacement device sales are projected to expand at a compound annual growth rate (CAGR) of 10.9% during 2016-21, increasing from approximately $4,834.7m in 2016 to an estimated $8,094.4m in 2021. Countries/regions covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of the World segment (which combines estimated sales data for all other countries).

July 1, 2017

Exelon

Novartis first launched Exelon as a twice-daily oral formulation in Europe in 1998 and in the US in 2000 for the treatment of mild to moderate Alzheimer’s disease.

September 2, 2016

Evinacumab

Evinacumab (Regeneron) is a monoclonal antibody (MAb) that inhibits angiopoietin-like 3 inhibitor (ANGPTL3). ANGPTL3 is secreted naturally by the liver and acts as a partial inhibitor of lipoprotein lipase and endothelial lipase.

November 20, 2018

Prezista franchise

The Prezista franchise comprises the standalone protease inhibitor (PI) Prezista (darunavir; Johnson & Johnson) and the fixed-dose combination of Prezista and Tybost (cobicistat; Gilead), which is branded as Prezcobix in the US and Rezolsta in the EU.

June 28, 2019

Kadcyla

Kadcyla (ado-trastuzumab emtansine; ImmunoGen/Roche/Chugai) is a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC), which contains the humanized anti-HER2 immunoglobulin G1 Herceptin.

March 9, 2015

Pressures and Opportunities in Pain

$2,995.00

This report summarizes the latest developments within pain, analyzing trends within regulatory approvals, clinical trials, and deal-making activities, gauging current physician perceptions, as well as looking forward to the catalysts set to change the future pain.

December 6, 2016

U.S. Markets for Orthopedic Biologic and Tissue Engineered Products

Tissue engineering, or regenerative medicine, represents a promising therapeutic possibility for the treatment of aggressive and deadly diseases.

September 22, 2016

Gilteritinib

Gilteritinib (Astellas) is an oral multi-tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK), Axl receptor tyrosine kinase, and FMS-like tyrosine kinase 3 (FLT3).

July 6, 2017

Disease Analysis: Non-Small Cell Lung Cancer (NSCLC)

Lung cancer is generally categorized as either small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC). Of these, NSCLC is the most common type of lung cancer, accounting for roughly 85% of all cases. NSCLC can be further divided into non-squamous and squamous NSCLC histologies. Squamous NSCLC refers to patients with squamous cell carcinoma, whereas non-squamous NSCLC includes patients with adenocarcinoma, large cell carcinoma, and other less common subtypes. Incidence of adenocarcinoma and squamous cell carcinoma varies greatly by both geographic region and gender. In general, adenocarcinoma comprises approximately 30–50% of all lung cancer cases, while squamous cell carcinoma accounts for roughly 25–35%.

July 22, 2022

Disease Analysis: Melanoma

Melanoma accounts for just 1% of all skin cancer cases, but is responsible for the majority of skin cancer-related deaths. Melanoma occurs when melanocytes – pigment-producing cells of the skin that are intercalated in the basal cell layer – become malignant. Although surgical excision is a potentially curative option for many melanoma patients, the disease can disseminate rapidly. Currently, only 27.3% of patients diagnosed with distant metastatic melanoma survive for five years, compared to about 99.0% of those with localized disease. Although 83% of patients present with localized disease, approximately one quarter to one third of these patients will eventually experience disease recurrence.

June 22, 2022